MARKET WIREStocktwits • 18h ago
STTK: Shattuck Labs Inc Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
Why STTK Stock dropped -2.80% Today — RQD Quant Desk Flash
$5.56 -2.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.52
Shattuck Labs Inc. (STTK) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $558.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on STTK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $5.56 (-2.80% 1D, market cap $558.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STTK ranks #826 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does STTK compare to NGNE and EVO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $551.3M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while GERN leads on capital efficiency (-20.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for STTK?
▼
Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.52 (-0.69%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STTK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY STTK SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.49+6.4% Next Q
21
Q2 (-2Q)Grade E$5.84-1.2% Next Q
24
Q3 (-1Q)Grade E$5.77-3.6% Next Q
26
CurrentGrade E$5.56-9.8% Hist 90D α
29
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a STTK Turnaround Squeeze
While STTK currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($5.84) forces dealer call-delta covering toward $8.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $STTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why STTK Stock dropped -2.80% Today — RQD Quant Desk Flash
Shattuck Labs Inc. (STTK) dropped -2.80% to $5.56, trading at 58% of its 52-week range ($1.72 – $8.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 58% of its 52-week range ($1.72 – $8.33) with RSI-14 at 43.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.56 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live STTK Headlines & Catalysts
MARKET WIREYahoo Finance • 21h ago
UBS Initiates Shattuck Labs at Buy With $17 Price TargetYahoo Finance report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
UBS initiates Shattuck Labs stock with buy rating on drug advantageInvesting.com report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
CATALYSTThe Globe and Mail • 1d ago
Leerink Partners Keeps Their Buy Rating on Shattuck Labs (STTK)The Globe and Mail report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Here's Why We're Not At All Concerned With Shattuck Labs' (NASDAQ:STTK) Cash Burn SituationSimply Wall St report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Shattuck Labs will present two antibody posters in Barcelona, one on inflammatory bowel disease.Stock Titan report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunologySeeking Alpha report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Shattuck Labs presents two UEG posters: what they mean for Shattuck Labs stockad-hoc-news.de report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 20d ago
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-clas
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STTK)
- ✓Walkthrough of STTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
STTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.65%📐 HORIZONTAL RANGE
2026-11-03O $5.72H $5.72L $5.56C $5.56VOL 951.5K
RES: $8.90SUP: $5.00SMA50: $6.20SMA200: $6.05
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
STTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on STTK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for STTK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STTK)
Health Care Rank #826 of 1016
⚔️ NGNE vs STTK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (STTK vs. NGNE, EVO, GERN, DRUG)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Shattuck Labs Inc. (STTK) ranks #826 by composite RQD confidence (29/100, grade E) and #424 by equity capitalization ($558.0M). Within this direct 5-issuer industry benchmark cohort, STTK leads on earnings valuation at N/A trailing P/E, while GERN leads on capital efficiency and profitability with -20.2% ROIC and — gross margin. EVO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with STTK at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STTK
ACTIVE
Shattuck Labs Inc. | E | 29/100 | — | — | -35.0% | -2.80% | $558.0M | Benchmark Subject |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -4.41% | $551.3M | /ngne-vs-sttk → |
| EVO Evotec SE | D | 47/100 | — | — | — | -3.16% | $544.3M | /evo-vs-sttk → |
| GERN Geron Corporation | E | 28/100 | — | — | -20.2% | -5.47% | $574.6M | /gern-vs-sttk → |
| DRUG Bright Minds Biosciences Inc. | D | 46/100 | — | — | — | -3.02% | $539.9M | /drug-vs-sttk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680367In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shattuck Labs Inc. (STTK) reported GAAP revenue of $1.0M (-82.5% vs. FY2024 revenue of $5.7M , and -39.6% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$39.9M, and free cash flow of -$40.0M (+34.0% YoY). On the balance sheet, STTK closed FY2025 with $91.0M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$48.8M | -$39.9M | -$40.0M | $91.0M | — |
| FY2024 (FY) | 2024-12-31 | $5.7M | -$75.4M | -$60.5M | -$60.6M | $91.0M | — |
| FY2023 (FY) | 2023-12-31 | $1.7M | -$87.3M | -$81.2M | -$81.2M | — | — |
3. STTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $5.56 (-2.80% 1D, market cap $558.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STTK ranks #826 in composite RQD confidence.
How does STTK compare to NGNE and EVO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $551.3M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while GERN leads on capital efficiency (-20.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for STTK?
Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is STTK trading relative to its 50-day, 200-day, and 52-week technical levels?
STTK last traded at $5.56 (-2.80% on volume of 951,482 shares), positioning the stock -10.32% below its 50-day simple moving average ($6.20) and -8.10% below its 200-day simple moving average ($6.05). Across its 52-week range of $1.72 to $8.33, STTK sits at the 58.1% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.87 to $6.25).
STTK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is STTK stock moving today?
Why STTK Stock dropped -2.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
STTK — Shattuck Labs Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:52Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, STTK scores 31 out of 100 for an letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -6.96%), Whale 13F Flow at 7/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 26; Piotroski F 3/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillar is insider conviction, which is the lowest of the five and signals limited insider-level confidence per the RQD rating. The cash engine and balance sheet pillars both sit at 8/20, reflecting negative return on invested capital and negative free cash flow yield alongside a balance sheet that carries a high Altman Z-Score and a low Piotroski F-Score of 3/9. The most constructive element is the whale and institutional flow pillar at 7/20, which indicates some institutional positioning activity, though it remains below the midpoint. Upside drivers would need to come from a change in the cash engine, since the rating reflects negative operating economics. Valuation tradeoffs are difficult to assess because P/E, forward P/E, and EV/EBITDA are not available in source data, so the stock cannot be framed against earnings-based benchmarks. The Beta of 1.0 implies market-level sensitivity, which the macro pillar scores modestly at 5/20.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.0M | $-51.5M | $-48.8M | N/A | $-40.0M | $54.2M | N/A |
| FY 2024 | $5.7M | $-80.6M | $-75.4M | N/A | $-60.6M | $57.4M | N/A |
| FY 2023 | $1.7M | $-92.0M | $-87.3M | N/A | $-81.2M | N/A | N/A |
Per the SEC financials, operating and net losses narrowed from FY 2023 through FY 2025 while revenue fluctuated, and the company reported operating margin of -60% and net margin of -60% alongside a gross margin of 0%. Return on invested capital is -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 3/9, with a Debt/Equity ratio of 0.5. Cash decreased from $57.4M to $54.2M between FY 2024 and FY 2025 per the SEC financials.
Recent Catalysts & News Wire Analysis
Per the recent news feed, UBS initiated coverage of Shattuck Labs at Buy with a $17 price target, and Leerink Partners maintained a buy rating; both are classified as market wire items, with the Leerink item flagged as a catalyst. Per the same feed, the company announced it will present two antibody posters in Barcelona, one on inflammatory bowel disease. A Simply Wall St item addressed the company's cash burn. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Risk watch items include continued operating losses and negative free cash flow in the SEC financials.
Open Questions
- What are the company's specific product candidates, and which clinical or regulatory milestones are scheduled?
- What is the current debt balance, since the FY 2025 debt figure is reported as N/A?
- What is the basis for the $17 UBS price target relative to the $5.72 current price, and what assumptions underlie it?
- What is the company's cash runway at the current FY 2025 burn rate of -$40.0M?
- What do the institutional and insider holdings look like, since the holders section is empty?
STTK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Shattuck Labs Inc. (STTK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 18h ago
STTK: Shattuck Labs Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 21h ago
UBS Initiates Shattuck Labs at Buy With $17 Price Target Yahoo Finance report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
UBS initiates Shattuck Labs stock with buy rating on drug advantage Investing.com report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST The Globe and Mail • 1d ago
Leerink Partners Keeps Their Buy Rating on Shattuck Labs (STTK) The Globe and Mail report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Here's Why We're Not At All Concerned With Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation Simply Wall St report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Shattuck Labs will present two antibody posters in Barcelona, one on inflammatory bowel disease. Stock Titan report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology Seeking Alpha report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Shattuck Labs presents two UEG posters: what they mean for Shattuck Labs stock ad-hoc-news.de report covering Shattuck Labs Inc. (STTK) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
STTK Bull vs. Bear Conversation Board — What's Your Call at $5.56?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STTK 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $5.03 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is STTK (E • RQD 31/100) a Buy at $5.72?
Welcome to the STTK (Shattuck Labs Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.40 (-23.1%)
Spot @ $5.72 Pump the brakes on STTK — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on STTK, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Shattuck Labs Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $6.92 (+21.0%)
Spot @ $5.72 STTK cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on STTK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.72 (52-wk range $1.72 - $8.33), any beat on forward guidance forces shorts and underweight funds to chase.